According to IMARC Group, the global liquid biopsy market was valued at USD 2.60 Billion in 2025 and is projected to reach USD 7.61 Billion by 2034, expanding at a CAGR of 12.31% during 2026–2034. This exceptional liquid biopsy market growth reflects surging demand for minimally invasive diagnostics, rapid advances in next-generation sequencing (NGS), expanding precision oncology adoption, and the global rise in cancer burden.

Liquid Biopsy Market Overview

Liquid biopsy refers to a minimally invasive diagnostic approach that captures and analyses tumour-derived components circulating in body fluids — primarily blood, but also urine, saliva, and cerebrospinal fluid. Key analytes include:

●        Circulating Tumour Cells (CTCs)

●        Circulating Tumour DNA (ctDNA)

●        Extracellular Vesicles (EVs) and exosomes

●        Tumour-educated platelets and circulating RNA

Applications span the entire oncology care pathway: early screening, companion diagnostics for therapy selection, minimal residual disease (MRD) detection post-treatment, recurrence surveillance, and emerging uses in transplant rejection monitoring and non-invasive prenatal testing (NIPT). The Liquid Biopsy Market Size is underpinned by these diverse clinical applications, driving adoption across hospitals, oncology clinics, and research centres worldwide.

Global Liquid Biopsy Market Size & Key Statistics

Below are the key liquid biopsy market statistics drawn from IMARC Group's comprehensive market analysis:

Request for a Sample Report for Detailed Market Insights Evaluation: https://www.imarcgroup.com/liquid-biopsy-market/requestsample

Key Market Drivers & Trends in 2026

Several powerful forces are shaping the Liquid Biopsy Market and fuelling strong double-digit growth expectations across global healthcare markets:

1. Rising Global Cancer Burden

GLOBOCAN 2022 estimated 19.97 million new cancer cases globally, with incidence projected to surpass 35 million by 2050. This structural rise in cancer incidence directly expands the liquid biopsy demand base, as healthcare systems urgently seek scalable, non-invasive tools for early detection and ongoing monitoring. The sheer scale of global oncology need is the primary structural driver behind Liquid Biopsy Market Growth.

2. Advances in Next-Generation Sequencing (NGS)

NGS costs have dropped dramatically over consecutive years, making comprehensive genomic profiling economically viable across community oncology settings. Illumina commands over 70% of the global NGS installed base in 2025, with platforms such as NovaSeq X and NextSeq 2000 serving as the technical backbone for liquid biopsy workflows. Cost reductions are unlocking broader adoption in both developed and emerging markets.

3. Precision Oncology and Companion Diagnostics

Over 100 FDA-approved targeted therapies now require molecular profiling, with approximately 40% accepting liquid biopsy as an alternative to invasive tissue sampling. This regulatory and clinical alignment is creating a structural, recurring demand for liquid biopsy tests as frontline companion diagnostics across oncology practice.

4. Multi-Cancer Early Detection (MCED) Commercialisation

MCED tests capable of screening 50+ cancer types from a single blood draw are transitioning from pilot programmes to commercial deployment. GRAIL's Galleri, supported by an NHS England trial with 140,000 participants, exemplifies the scale of potential adoption. MCED represents the largest single growth opportunity within the Liquid Biopsy Market, targeting a USD 2+ Billion addressable opportunity by 2030.

5. ctDNA-Based Minimal Residual Disease (MRD) Monitoring

Post-treatment ctDNA surveillance is the fastest-growing clinical application within the liquid biopsy landscape. Natera's Signatera, Guardant Reveal, and NeoGenomics' RaDaR are competing for standard-of-care integration across adjuvant protocols in colorectal, breast, and lung cancer. MRD monitoring is projected to represent a USD 1.5–2 Billion market opportunity by 2030.

6. Growing Healthcare Data Security and Regulatory Infrastructure

Robust regulatory frameworks — including FDA approvals of Guardant360 CDx and FoundationOne Liquid CDx, CMS National Coverage Determinations, and Europe's IVDR framework — are building clinical and payer confidence in liquid biopsy. These approvals validate test accuracy, support reimbursement, and encourage broader healthcare provider adoption.

7. AI and Machine Learning in Variant Interpretation

AI models are increasingly deployed in variant calling, fragmentomics, and methylation signature interpretation. Delfi Diagnostics' FirstLook lung cancer test leverages AI-based fragmentomics as its core differentiation. Tempus Labs, Caris, and GRAIL deploy proprietary AI pipelines integrating genomic, methylomic, and clinical outcomes data — significantly enhancing diagnostic accuracy and Liquid Biopsy Market Share for technology leaders.

Key Market Segmentation

By Product and Service

Kits and Reagents – Largest Segment (46.9% share, 2025)

Kits and Reagents command the largest liquid biopsy market share, driven by the recurring per-test consumable economics of liquid biopsy workflows. Every clinical test consumes USD 300–800 in cfDNA extraction kits, library preparation reagents, and enzymes — creating a revenue base that grows in lockstep with test volume. QIAGEN, Thermo Fisher Scientific, and Roche lead this segment with comprehensive workflow portfolios.

Platforms and Instruments – 29.8% share, 2025

Platforms and Instruments represent the capital-equipment layer, dominated by Illumina's NovaSeq and NextSeq series alongside Bio-Rad's QX600 Droplet Digital PCR platform for sensitive MRD applications. Capital investment in platforms drives sustained reagent and services revenue.

Services – 23.3% share, 2025

Services capture outsourced clinical testing volume handled by specialty CLIA-certified laboratories such as Guardant Health, Natera, and NeoGenomics. This segment is growing as hospitals and oncology clinics increasingly prefer to outsource complex genomic testing.

By Circulating Biomarker

Circulating Tumour Cells (CTCs) – Largest (33.7%, 2025)

CTCs dominate the biomarker segment, supported by FDA-cleared platforms such as Menarini Silicon Biosystems' CellSearch for breast, prostate, and colorectal cancer monitoring — reflecting over two decades of clinical validation.

Circulating Tumour DNA (ctDNA)

ctDNA at 28.6% in 2025 is the fastest-growing biomarker at ~14.2% CAGR, propelled by MRD monitoring applications and comprehensive genomic profiling workflows.

Extracellular Vesicles (EVs)

EVs at 21.4% are gaining traction in prostate, pancreatic, and lung cancer diagnostics, offering enhanced protein and RNA content as a complementary approach to ctDNA.

By Cancer Type

Applications span Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Others. Lung cancer represents one of the most active segments given the availability of FDA-approved companion diagnostics (e.g., cobas EGFR Mutation Test) and high unmet need for repeat, non-invasive monitoring.

By End User

Hospitals and Laboratories – Largest End-User Segment

Hospitals and clinical laboratories account for the largest end-user share given high patient volumes, multi-specialty oncology departments, and integration of liquid biopsy into standard cancer care pathways.

Academic and Research Centres

Academic institutions drive clinical validation studies, novel biomarker discovery, and pharmaceutical trial sponsorship that ultimately accelerates commercial adoption.

Regional Market Analysis

Connect for Detailed Segmentation Analysis – Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=5125&flag=C

Leading Players in the Liquid Biopsy Industry

The global liquid biopsy market features a mix of diversified diagnostics giants and focused pure-play innovators. Key companies covered in the IMARC Group report include:

●        F. Hoffmann-La Roche Ltd (AVENIO ctDNA Kits, FoundationOne Liquid CDx)

●        Guardant Health Inc. (Guardant360 CDx, Guardant Reveal, Shield)

●        Illumina Inc. (NovaSeq X, TruSight Oncology 500 ctDNA)

●        Thermo Fisher Scientific Inc. (MagMAX, Ion Torrent platforms)

●        Natera, Inc. (Signatera, Constellation)

●        Bio-Rad Laboratories, Inc. (QX200/QX600 Droplet Digital PCR)

●        NeoGenomics Laboratories (NEO PanTracer LBx, RaDaR MRD)

The report includes competitive analysis covering market structure, player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant to support strategic decision-making.

Latest Industry Developments

September 2023 – F. Hoffmann-La Roche Ltd

Roche France, Foundation Medicine, Inc., and the Institut Gustave Roussy announced a unique partnership to establish in-house liquid biopsy testing at Institut Gustave Roussy's facilities in France by transferring technology from Foundation Medicine's FoundationOne Liquid CDx — expanding access to comprehensive genomic profiling at a leading European cancer centre.

July 2024 – Guardant Health, Inc.

The FDA approved Guardant Health's Shield blood test for primary colorectal cancer screening in average-risk adults aged 45 and older — the first FDA-approved blood-based colorectal cancer screening test — significantly expanding the addressable Liquid Biopsy Market Share from advanced cancer into population-scale screening.

November 2024 – Illumina, Inc.

Illumina announced the development of TruSight Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay enabling comprehensive genomic profiling, with global release planned for mid-2025 — reinforcing its position as the dominant NGS platform provider for liquid biopsy workflows.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Construction, Healthcare, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104